Close Menu

NEW YORK – GlaxoSmithKline yesterday announced that new data from its ongoing Phase I/II GARNET study evaluating the anti-PD-1 monoclonal antibody dostarlimab showed the drug provided clinically meaningful results among women with recurrent or advanced mismatch repair-deficient (dMMR) endometrial cancer who had disease progression during or after a platinum-based treatment regimen.

The data were accepted as a late-breaking abstract and presented as part of the Society of Gynecologic Oncology's 2020 virtual congress.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.